Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug composite for preventing diabetic nephropathy and preparation method thereof

A technique for diabetic nephropathy and its composition, which is applied in the field of preparation of drugs for preventing and treating diabetic nephropathy, can solve the problems of no reports, etc., and achieve the effects of clear structure, easy quality control, and prevention of the increase of blood creatinine

Active Publication Date: 2010-07-21
广州康臣药业有限公司
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although it has been reported in the literature that they have various pharmacological activities, there is no report at home and abroad on the effect of calycosin and its glycosides on the prevention and treatment of diabetic nephropathy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composite for preventing diabetic nephropathy and preparation method thereof
  • Drug composite for preventing diabetic nephropathy and preparation method thereof
  • Drug composite for preventing diabetic nephropathy and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Preparation of mullein and mullein glycosides

[0036] Take 10 kg of dried astragalus medicinal materials, extract 3 times (2 hours, 1 hour, 1 hour) with 8 times the amount of 80% ethanol under reflux, filter, combine the filtrate, recover the solvent under reduced pressure, and concentrate until no alcohol taste to obtain the alcohol extract of astragalus. Placed in a refrigerator at 4°C overnight, the supernatant was adsorbed with D101 type macroporous resin, first eluted with pure water until the effluent was clear, and then eluted with 50% ethanol until TLC detected no verbasin spots. The 50% ethanol eluate was collected and concentrated under reduced pressure, and then extracted 7 times with an equal volume of ethyl acetate. After the extracts were combined, the solvent was recovered and dried under vacuum to obtain the total flavonoids of astragalus. The total flavonoids of Astragalus were then chromatographed on 200-300 mesh silica gel column with chlorof...

Embodiment 2

[0040] Example 2 Preparation of granules of pharmaceutical composition of the present invention (active ingredient is verbasil glycoside)

[0041] Verbascum glycosides 1mg

[0042] Starch 500mg

[0043] Microcrystalline cellulose 500mg

[0044] The preparation method: after mixing the verbasil glycosides with various auxiliary materials uniformly, the soft material is prepared with an appropriate amount of water, granulated, dried, granulated, and packed.

Embodiment 3

[0045] Example 3 Preparation of a tablet of the pharmaceutical composition of the present invention (active ingredient is verbasil glycoside)

[0046] Verbascum glycosides 20mg

[0047] Lactose 127mg

[0048] Corn starch 50mg

[0049] Magnesium stearate 3mg

[0050] Preparation method: Pass the Verbasil glycosides through an 80-mesh sieve, mix them with lactose and corn starch uniformly, add an appropriate amount of water and granulate the powder, after drying, the granules are sieved and mixed with other excipients, and then compressed into tablets. .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composite for preventing diabetic nephropathy and application to preparing medicines for treating diabetes-related complications; the drug composite is composed of one or two of active ingredients-calycosin and calycosin-7-0-D-glucopyranpside, and a carrier which is acceptable in pharmacy; the content of the active ingredients is 0.1-99.5 percent; the drug composite is mainly applied to preparing medicines for treating diabetes-related complications; the drug composite has obvious prevention function to the diabetic nephropathy, the usage is convenient, the quality is controllable, so as to provide new drug candidate for treatment.

Description

Technical field [0001] The invention relates to the field of Chinese medicine pharmacy. Specifically, it relates to a medicinal composition with mullein and mullein glycosides as active ingredients and its application in preparing drugs for preventing and treating diabetic nephropathy. Background technique [0002] Diabetic nephropathy (diabetic nephropathy, DN) is a common complication of diabetes and one of the manifestations of diabetic systemic microangiopathy. It usually refers to the thickening of glomerular basement membrane, mesangial expansion and extracellular matrix proliferation caused by diabetes, leading to the kidney High filtration and proteinuria of the pellet. The clinical features are proteinuria, progressive renal impairment, hypertension, edema, and severe renal failure in the late stage, which is one of the main causes of death in patients with diabetes. According to statistics, about 30-40% of diabetic patients will experience kidney damage. In the Unite...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/7048A61P3/10A61P13/12C07H1/00C07H17/07C07D311/36
CPCA61K31/7048A61K31/352A61P13/12A61P3/10
Inventor 朱荃石兴华汤丹郑兆广何宝段婷婷顾斐程慧荃黄晓玲黄艳霞王汝上
Owner 广州康臣药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com